Inscripta (formerly known as Muse Biotechnology) was founded in 2015 by Andrew Garst, Ryan Gill, and Tanya Lipscomb. Following a 2021 funding round, a company spokesperson told reporters that Inscripta has no plans to go public in the near future.
Inscripta is the developer of a genomic engineering platform. Genomic engineering, more commonly known as "gene editing," is the process by which scientists can modify the genetic blueprint of a living organism. Researchers have used the process to modify yeast cells so that the organisms will produce useful byproducts such as fuel, or chemicals with medicinal applications. Inscripta has raised more than $400 million in venture capital funding from investors such as Fidelity Management, T. Rowe Price, and D1 Capital Partners. A company spokesperson declined to offer valuation figures following the 2021 funding round.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Inscripta does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.
The stock price for Inscripta will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 4/5/2021 | Series E | $1.32B | $XXX.XX | $XXX.XX |
| 11/13/2020 | Series D | $594.94MM | $XXX.XX | $XXX.XX |
| 4/19/2019 | Series C-1 | $278.92MM | $XXX.XX | $XXX.XX |
| 2/28/2018 | Series C | $182.26MM | $XXX.XX | $XXX.XX |
| 2/28/2017 | Series B | $48.64MM | $XXX.XX | $XXX.XX |
| 5/30/2016 | Series A | $13.41MM | $XXX.XX | $XXX.XX |
Inscripta is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Inscripta pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Inscripta is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
